The “Real world outcomes across the Alzheimer’s disease spectrum for better care: multi-modal data access platform” (ROADMAP) project provides the foundation for an integrated data environment and framework for real world evidence (RWE in Alzheimer’s disease).

This includes the development of consensual key outcome measures and data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP has a budget of EUR 7.77 million and 24 partners led by the University of Oxford and Novartis.

 

“Successfully delivering therapies to the tens of millions in need will depend on building a sustainable approach that addresses the challenges and opportunities around treatment access at time of approval. In AD this will very much depend on the integration of Real World Evidence (RWE) within health care systems to support evidence for approval as well as Health Technology Assessment and funding allocation.”

Project Leader and WorldWide Market Access Director NS at Novartis

Frédéric de Reydet de Vulpillieres
Subscribe to our newsletter!